Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
Inventors
Lozano Soto, Francisco • MARTINEZ FLORENSA, Mario
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11324804-B2
Publication Date
2022-05-10
Expiration Date
Abstract
The present invention relates to the field of medicine and provides compositions and kits-of-parts comprising a CD6 product and Imipenem, in particular for their use in a therapeutic and/or preventive method of treatment, in a mammal including a human, of an infectious disease, or of an inflammatory condition related to an infectious disease, or of an inflammatory disease related to the presence of a product derived from an infectious agent.
Core Innovation
The invention provides a method for therapeutic treatment of an infectious disease, an inflammatory condition related to an infectious disease, or an inflammatory disease related to the presence of a product derived from an infectious agent. The method comprises administering a composition comprising a CD6 product, or a derivative thereof, or an isoform thereof, together with Imipenem to a mammal in need thereof, and the combined administration is characterized by an at least additive effect relative to administering CD6 product and imipenem as single agents.
In particular embodiments, a soluble CD6 ectodomain is administered as a recombinant soluble CD6 product, including a recombinant soluble CD6 with SEQ ID NO:1. The combination can further include Cilastatin, and the CD6 product and Imipenem can be administered simultaneously, sequentially, or separately, via parenteral administration such as intraperitoneal and/or intravenous routes.
The content further describes comparative findings in which CD6 alone shows time- and dose-dependent survival benefits, whereas CD6 combined with imipenem provides at least additive improvements in survival along with reductions in systemic inflammation and bacterial load in the context of polymicrobial CLP-induced sepsis, septic shock, and SIRS. An additive effect is observed specifically with imipenem, while combinations of imipenem with other broad-spectrum antibiotics such as erythromycin or meropenem show non-additive outcomes.
Claims Coverage
The partial claims content provides two independent claims. Both require co-administering a CD6 product, or derivative or isoform thereof, with Imipenem to a mammal, with an at least additive effect versus single-agent administration.
At-least-additive CD6 product and Imipenem co-administration for therapeutic treatment
A method of therapeutic treatment comprising administering a composition comprising a CD6 product, or a derivative thereof, or an isoform thereof, and Imipenem to a mammal in need thereof, wherein there is an at least additive effect for the combined administration relative to their administration as single agents.
Simultaneous, sequential, or separate CD6 product and Imipenem co-administration with at-least-additive effect
A method of therapeutic treatment in which a CD6 product, or a derivative thereof, or an isoform thereof, and Imipenem are administered simultaneously, sequentially or separately to a mammal in need thereof, wherein there is an at least additive effect for the combined administration relative to their administration as single agents.
Across the two independent claims, the inventive focus is on co-administering a CD6 product, including derivatives or isoforms, together with Imipenem to obtain an at least additive therapeutic effect versus single agents, with one claim adding administration timing flexibility.
Stated Advantages
At least additive effect for the combined administration of the CD6 product and imipenem compared with their administration as single agents.
CD6 combined with imipenem produces at least additive improvements in survival.
CD6 combined with imipenem reduces systemic inflammation.
CD6 combined with imipenem reduces bacterial load.
Documented Applications
Prophylactic or therapeutic treatment in infectious diseases and related inflammatory conditions, including polymicrobial CLP-induced sepsis, septic shock, and SIRS.
Interested in licensing this patent?